Looking further at diabetes medications where there have been some concerns in the past, it seems fair to state that contrary to earlier fears, there seems to be no increased risk related to the use of insulin glargine, as evidenced in randomized controlled studies [57,58], or other forms of insulin, whilst bias by indication may play a role in observational data [39,58]. The gene discussed is INS; the disease is diabetes mellitus.